MKMohadeseh Karimian

Mohadeseh Karimian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohadeseh Karimian has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enhancing Cancer Immunotherapy with Berberine and Its Loaded Nanoparticles: A Systematic Review

    by Mohadeseh Karimian, Saber Abbaszadeh, Kosar Farhadi Babadi, Alizamen Salehifard Jouneghani, Saeid Heidari-Soureshjani, Catherine Mt Sherwin

    Introduction/Objective: Neoplasms are considered a health problem around the world. This study systematically examines the effects of Berberine (BBR) and BBR-loaded Nanoparticles (NPs), with an emphasis on elucidating the molecular and cellular mechanisms through which these formulations enhance cancer immunotherapy. Methods: A systematic literature search (on December 17, 2025) was conducted in PubMed, Scopus, Web of Science, and the Cochrane Library electronic databases. Related articles aligned with our study aim were screened, and the required data were extracted and recorded in a table. Moreover, the risk of bias for both in vitro and in vivo publications was assessed. Results: Finally, 22 studies were included in the screening process. BBR and its NPs potentially improved immunotherapy outcomes by reducing Programmed Cell Death 1 Receptor (PD-L1) expression (relieving PD-1/PD-L1-mediated immunosuppression), cytokine modulation, immune cell activation and infiltration, repolarization of macrophages from M2 to M1 phenotype, increasing T-cell-mediated cytotoxicity, disrupting mitochondrial membrane potential, and promoting the accumulation of intracellular Reactive Oxygen Species (ROS), inducing pyroptosis and immunogenic cell apoptosis in various cancerous cell lines. BBR NPs reduced systemic toxicity, improved sustained drug release, solubility, and drug targeting in tumor cells. Discussion: BBR and nanoformulated BBR enhance immunotherapy and drug delivery. However, limitations of this review were a lack of standardized study design techniques and clinical trial studies. Future studies should focus on cell toxicity, dose-effectiveness, and clinical translation. Conclusion: BBR and its NPs showed favorable immunomodulatory properties and enhanced cancer immunotherapy in experimental studies. However, more clinical studies are needed in this field.

  • Factors Associated With Post-Vaccination COVID-19 Infection Leading to Hospitalization in Chaharmahal and Bakhtiari Province: A Case-Control Study

    by Kosar Farhadi Babadi, Seyed Saeed Hashemi Nazari, Amir Kavousi, Ali Ahmadi, Mohadeseh Karimian

    Introduction: COVID-19 vaccination and its associated complications have been a controversial issue worldwide. This study aimed to identify the determinants of infection leading to hospitalization following COVID-19 vaccination in Chaharmahal and Bakhtiari Province. Methods: In this case-control study, after screening records from 47,001 individuals, 260 hospitalized vaccinated individuals were selected as cases, while 130 vaccinated outpatients and 130 healthy individuals were included as controls (n = 520). Data were analyzed by Stata 17 using descriptive and inferential statistics, including univariate and multivariable analyses and ordinal logistic regression models. Results: Multivariable analyses revealed older age (> 55 years, OR = 11.08, P < 0.001), female gender (OR = 0.45, P = 0.002), prior infection (OR = 292.7, P = 0.001), and non-healthcare occupations (OR = 2.07, P = 0.036) as significant risk factors for hospitalization, while being male (OR = 0.45, P = 0.002) and a healthcare worker (OR = 0.22, P = 0.006) were protective. Moreover, the Sinopharm (OR = 2.40, P = 0.012) and other vaccines (OR = 2.54, P = 0.036) were associated with higher hospitalization risk compared to AstraZeneca. Additionally, the protective effect of vaccination and underlying disease decreased over time (underlying disease HR = 0.99, P = 0.014; homologous booster HR = 0.99, P < 0.001; heterologous booster HR = 0.99, P = 0.025). Conclusion: Age, gender, comorbidities, recent hospitalization, and high-risk occupation influenced COVID-19 hospitalization, while prior infection and vaccination provided temporary protection, underscoring the need for targeted, time-sensitive interventions.

  • Chrysin and its nanoformulations in cancer therapy: A systematic review of their radiosensitizing, phototherapy-enhancing potentials

    by Mojtaba Saedi Marghmaleki, Mohadeseh Karimian, Elham Raeisi

    Introduction: Chrysin (CHY) is a naturally occurring flavonoid known for its anti-inflammatory and antioxidant properties. This systematic review aims to evaluate the photosensitizing and radiosensitizing effects of CHY and its nanoparticle (NP) formulations, and their potential to enhance therapeutic efficacy while reducing treatment-related adverse effects. Methods: This systematic review included 14 in vivo and in vitro studies published before October 21, 2025, that met specific inclusion and exclusion criteria. After screening, 14 studies met the inclusion criteria. Then information from each study was extracted and recorded. Subsequently, a risk-of-bias assessment was conducted for experimental studies, followed by a final analysis of the results. Results: CHY and its NPs, when combined with radiotherapy (RT) and phototherapy (PT), generate singlet oxygen (¹O₂) and various reactive oxygen species (ROS), causing photooxidative damage, DNA injury, cell-cycle arrest often at the G1 phase, and apoptotic cell death. Beyond direct cytotoxicity, CHY participates in key regulatory signaling pathways, including the modulation of apoptotic pathways, thereby enhancing apoptotic responses while increasing the production of inflammatory mediators. Under RT conditions, CHY and its nanoformulations boost γ-irradiation-induced tumor suppression by shifting the redox balance toward oxidative stress, increasing caspase-3 activity, and downregulating survival markers. Conversely, CHY shows notable protective effects in normal cells by reducing oxidative stress, neuroinflammation, and DNA damage through restoring antioxidant defenses, lowering lipid peroxidation, and maintaining neuronal integrity. Conclusion: Overall, CHY and its NPs suggest potential dual roles based on preclinical evidence as photo- and radiosensitizers while also providing protective effects against therapy-induced adverse outcomes.